July 11 - China accuses pharma giant GlaxoSmithKline of bribery and corruption, in the highest profile probe since 2010, when four Rio Tinto executives were jailed. Kirsty Basset reports
Bribery and tax law violation. China's accused GlaxoSmithKline of both - in the biggest case of graft involving a foreign firm in China, in three years. The charges include offering bribes to Chinese government officials, medical associations, hospitals and doctors - to boost sales and prices. China also says GSK violated the tax law by faking receipts. Its security minister says it's received confessions from the executives. But it's not said how many - or who they are. GSK says it's taking the allegations seriously. And always tries to ensure it meets strict compliance procedures. But it's found no evidence of bribery or corruption to support China's claims. It's the highest profile probe in China since 2010, when four executives from mining giant Rio Tinto were jailed for taking bribes and stealing commercial secrets.